| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |